Verein für
Association pour le
Associazione per il

medizinische Qualitätskontrolle
contrôle de qualité médical
controllo di qualità medico

Survey Report

2024 - 3

MQ, Universitätsspital Zürich, 8091 Zürich
Telefon 044 255 34 11, www.MQZH.ch, info@MQZH.ch

Survey Specimens
The homogeneity and stability of all specimens were checked before and/or during shipment and no irregularities were noted. The suitability tests were performed by the laboratories of the Universitätsspital Zürich (University Hospital Zurich) (http://www.uzl.usz.ch/).
The following survey specimens were produced specifically for MQ by a sub-contractor:
B2 Uricult, H4 Parasitic Hematology, K14 tumor marker

Determination of target values

For each target value, the type of determination per ISO17043: 2010 B2.1 is indicated (column "type"):
a Value known due to production.
b Certified reference value for use with special specimens
c Reference value determined by analysis
d Consensus values of expert laboratories
e Consensus values of the participants

For methods groups with more than 9 participants, consensus values of the participants ("e") are generally determined.
In order to calculate the target values, we use the mean value of the method group. Values that differ more than 1.5 times the QUALAB-tolerance are outliers and are not used to calculate the target value. Starting point for the elimination of outliers are the values of our suitability tests.
In order to provide all participants with target values that are as meaningful as possible, other methods may also be applied for smaller method groups.

Uncertainty of the determined target values
The standard uncertainty (u_x) is calculated using the following formula (ISO13528):
ux = (target value/100) * (1.25/square root of "number of participants") * %CV

- ux has the same unit as the target value
- ux can be compared with the standard deviation of the participants' collective (SD=target value*%CV/100)
- For participant numbers >18, the standard uncertainty (ux) is significantly lower than the scatter of the collective participants and can be neglected.

QUALAB and MQ tolerances

For all mandatory analyzes, QUALAB tolerances are used (www.qualab.ch, external quality control). For non-mandatory analyzes, the tolerances are specified by MQ's survey specimen leader.

If the determined uncertainty, ux, of the target value is greater than 15% of the QUALAB or MQ tolerance, the letter indicating the type of target detection is marked with an additional star (example "e*"). Thereby, we are alerting the participants to the fact that the uncertainty of the target value can have an impact on the evaluation.

Graphics

The results are shown graphically as follows:



Comparison of Devices
The data in this report allows you to compare the performance of different devices. However, remember to consider the following:

- The chemical control K1 is a ready-to-use commercial control serum. Even if the specimen is of human origin, it is possible that matrix effects occur. These are device-specific and result in different target values.
- Only one specimen was measured. Since the scatter of the results is dependent on the nature of the specimen (matrix effects) and on the signal strength, the determined coefficient of variations (CV in %) cannot be applied generally.
- A large number of runaways is due to administrative errors (wrong unit, results mixed up) or to operator errors (wrong sample, not correctly taken up in solution, not mixed well) and has nothing to do with the type of device.

.

Zürich, 1.10.2024

Dr. R. Fried
Survey Director

.

INR



QUALAB tolerance : 15 %

INR ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	16	100.0	0.0	0.0	1.53	4.0	e
2	Neoplastin R	15	100.0	0.0	0.0	1.67	5.0	e
3	Neoplastin Plus	8	100.0	0.0	0.0	2.08	6.0	e*
4	Recombiplastin 2G	14	100.0	0.0	0.0	1.68	4.4	e
5	Other methods	13	100.0	0.0	0.0	1.64	6.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Fibrinogen OA



QUALAB tolerance : 15 %

Fibrinogen OA (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	8	75.0	25.0	0.0	1.01	11.9	e*
2	Stago/STA	20	100.0	0.0	0.0	1.14	5.0	e
3	Fibrinogen Q.F.A.	8	100.0	0.0	0.0	1.06	8.1	e*
4	Other methods	6	100.0	0.0	0.0	1.13	5.9	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Activated Prothrombin Time



QUALAB tolerance : 25 %

Activated Prothrombin Time (Sek)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	6	100.0	0.0	0.0	38.1	5.7	e
2	Pathromtin SL	7	100.0	0.0	0.0	58.6	4.6	e
3	Stago/STA	22	100.0	0.0	0.0	50.3	5.4	e
4	aPTT-SP	9	100.0	0.0	0.0	40.0	5.6	e
5	Other methods	11	100.0	0.0	0.0	39.4	8.7	e

INR CoaguChek



QUALAB tolerance : 15 %
(< 1.3: +/- 0.2)

INR CoaguChek ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	886	98.3	0.7	1.0	1.2	2.8	e

Prothrombin time NT



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	12	100.0	0.0	0.0	100	0.0	e
2	Neoplastin R	12	100.0	0.0	0.0	97	3.5	e
3	Neoplastin Plus	4	100.0	0.0	0.0	99	3.7	e*
4	STA-NeoPTimal	7	100.0	0.0	0.0	92	5.0	e*
5	Recombiplastin 2G	10	100.0	0.0	0.0	100	0.0	e
6	Other methods	15	100.0	0.0	0.0	99	1.4	e

Fibrinogen N



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	10	100.0	0.0	0.0	2.66	8.2	e*
2	Stago/STA	17	100.0	0.0	0.0	3.00	5.0	e
3	Fibrinogen Q.F.A.	14	100.0	0.0	0.0	2.67	4.7	e
4	Fib Clauss (IL)	5	100.0	0.0	0.0	2.86	7.3	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Faktor V



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	87.5	12.5	0.0	95.5	15.8	e*

aPTT N



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	12	100.0	0.0	0.0	22.8	6.1	e
2	Pathromtin SL	6	100.0	0.0	0.0	37.7	7.1	e
3	Stago/STA	20	100.0	0.0	0.0	31.5	5.8	e
4	aPTT-SP	11	90.9	9.1	0.0	27.7	9.6	e
5	Other methods	5	100.0	0.0	0.0	36.0	1.9	e

Faktor VII



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	109.4	5.8	e

Prothrombin time HT



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	13	100.0	0.0	0.0	104	4.5	e
2	Neoplastin R	13	100.0	0.0	0.0	97	5.6	e
3	Recombiplastin 2G	11	100.0	0.0	0.0	101	3.0	e
4	Other methods	11	90.9	9.1	0.0	103	7.3	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-FXa (unfrakt-Heparin)



MQ tolerance : 20 %

Anti-FXa (unfrakt-Heparin) (IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	12	100.0	0.0	0.0	0.08	21.5	a
2	ACL	25	100.0	0.0	0.0	0.24	11.4	a
3	Other methods	12	100.0	0.0	0.0	0.26	13.4	a

Fibrinogen H



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	4	100.0	0.0	0.0	3.19	6.6	e*
2	Stago/STA	16	100.0	0.0	0.0	3.22	4.6	e
3	Fibrinogen Q.F.A.	12	100.0	0.0	0.0	2.97	4.5	e
4	Other methods	10	100.0	0.0	0.0	2.99	5.2	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

aPTT H



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	4	100.0	0.0	0.0	31.0	1.6	e
2	Actin FSL	5	100.0	0.0	0.0	32.6	5.2	e
3	Pathromtin SL	7	100.0	0.0	0.0	55.0	6.6	e
4	Stago/STA	14	100.0	0.0	0.0	48.8	7.3	e
5	aPTT-SP	11	100.0	0.0	0.0	45.8	4.5	e
6	Other methods	4	100.0	0.0	0.0	33.0	3.1	e

D-dimer



QUALAB tolerance : 21 %

D-dimer (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche (Zitratplasma)	9	88.9	11.1	0.0	0.58	12.3	e*
2	STA Liatest	17	94.1	0.0	5.9	0.52	11.8	e*
3	Siemens Innovance	12	100.0	0.0	0.0	1.02	8.2	a
4	Pathfast	23	82.7	4.3	13.0	2.78	11.3	e
5	ACL	16	93.7	0.0	6.3	1.06	9.7	e
6	AQT 90 FLEX	5	100.0	0.0	0.0	0.39	6.3	e*
7	VIDAS	16	93.7	6.3	0.0	0.77	8.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

D-Dimer Triage



QUALAB tolerance : 21 %

D-Dimer Triage (ng/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	195	93.3	4.1	2.6	385.17	10.7	e

D-dimer qn AFIAS



QUALAB tolerance : 21 %

D-dimer qn AFIAS (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	441	78.6	7.3	14.1	0.55	11.9	e

CoaguChek APTT



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	7	100.0	0.0	0.0	40.4	7.1	e

INR CCXS



QUALAB tolerance : 15 %

INR CCXS ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek XS	1322	99.3	0.2	0.5	2.8	3.6	e

INR HC



QUALAB tolerance : 15 %

INR HC ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hemochron j.	6	83.3	0.0	16.7	5.2	7.1	e*

INR MI



QUALAB tolerance : 15 %

INR MI ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	microINR Expert	14	78.6	21.4	0.0	2.0	9.6	e*
2	MicroINR	112	74.1	8.9	17.0	2.0	7.5	e

INR Xprecia



QUALAB tolerance : 15 %

INR Xprecia ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Xprecia	44	95.5	0.0	4.5	3.0	3.2	e

INR Lumira Dx



QUALAB tolerance : 15 %

INR Lumira Dx ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	7	85.7	14.3	0.0	4.7	13.3	e*

Anti-FXa (LMW-Heparin)



MQ tolerance : 20 %

Anti-FXa (LMW-Heparin) (IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	14	100.0	0.0	0.0	1.80	6.4	e
2	ACL	23	100.0	0.0	0.0	1.75	8.9	e
3	Other methods	12	91.7	0.0	8.3	1.67	12.4	e*

Anti-FXa (Rivaroxaban)



MQ tolerance : 20 %

Anti-FXa (Rivaroxaban) (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	14	100.0	0.0	0.0	320.26	4.5	e
2	ACL	10	100.0	0.0	0.0	312.16	8.5	e*

Anti-FXa (Apixaban)



MQ tolerance : 20 %

Anti-FXa (Apixaban) (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	8	100.0	0.0	0.0	61.34	9.6	a
2	ACL	5	100.0	0.0	0.0	72.80	3.2	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-FXa (Edoxaban)



MQ tolerance : 20 %

Anti-FXa (Edoxaban) (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	44.00	8.2	e*

Anti-FIIa (Dabigatran)



MQ tolerance : 20 %

Anti-FIIa (Dabigatran) (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	56.00	10.3	e*

Hemoglobin



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hemocue Hb 801	6	83.3	0.0	16.7	137.0	3.1	e*
2	Automat	9	100.0	0.0	0.0	117.0	3.9	e*
3	Cyanmethemoglobin	13	92.3	7.7	0.0	112.2	4.6	e*
4	Sysmex X	58	98.3	1.7	0.0	116.3	2.3	e
5	Hemocue	386	94.0	1.3	4.7	114.0	3.0	e
6	Hemocontrol	14	100.0	0.0	0.0	114.4	2.7	e
7	DiaSpect	13	76.9	7.7	15.4	110.0	5.8	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex KX21	92	100.0	0.0	0.0	115.8	1.4	e
2	Sysmex PocH - 100i	179	97.8	1.1	1.1	114.6	2.7	e
3	Sysmex XP 300	565	97.7	0.4	1.9	115.7	1.7	e
4	Mythic	217	96.7	0.5	2.8	112.7	2.7	e
5	Sysmex XQ-320	152	94.7	0.0	5.3	116.9	1.5	e
6	Swelab	27	92.6	3.7	3.7	119.3	3.3	e
7	Celltac Alpha (Nihon	52	96.2	0.0	3.8	118.9	2.6	e
8	Samsung HC10	6	100.0	0.0	0.0	116.0	1.7	e
9	Micros 60	53	100.0	0.0	0.0	112.7	2.8	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	5	80.0	0.0	20.0	0.32	1.6	e
2	Sysmex X	58	100.0	0.0	0.0	0.33	2.9	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	151	95.4	1.3	3.3	0.32	2.8	e
2	Sysmex KX21	92	98.9	1.1	0.0	0.32	2.5	e
3	Sysmex PocH - 100i	179	97.8	1.1	1.1	0.33	3.2	e
4	Sysmex XP 300	567	97.7	0.7	1.6	0.31	2.3	e
5	Mythic	217	96.3	0.0	3.7	0.32	3.3	e
6	Swelab	27	92.6	0.0	7.4	0.33	3.6	e
7	Celltac Alpha (Nihon	52	82.7	9.6	7.7	0.32	4.2	e
8	Samsung HC10	6	100.0	0.0	0.0	0.34	4.1	e*
9	Micros 60	53	96.2	3.8	0.0	0.30	4.0	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	6	83.3	16.7	0.0	3.73	15.2	e*
2	Sysmex X	58	100.0	0.0	0.0	3.69	2.8	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	151	97.4	1.3	1.3	3.85	5.4	e
2	Sysmex KX21	92	100.0	0.0	0.0	3.73	2.3	e
3	Sysmex PocH - 100i	179	98.8	0.6	0.6	3.81	3.9	e
4	Sysmex XP 300	567	98.0	0.4	1.6	3.71	3.2	e
5	Mythic	217	97.7	0.5	1.8	3.71	4.3	e
6	Swelab	27	96.3	0.0	3.7	3.69	3.9	e
7	Celltac Alpha (Nihon	52	98.1	0.0	1.9	3.82	2.8	e
8	Samsung HC10	6	100.0	0.0	0.0	3.81	3.7	e
9	Micros 60	53	96.2	1.9	1.9	3.63	5.0	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	5	100.0	0.0	0.0	4.60	8.0	e*
2	Microscopic	4	100.0	0.0	0.0	4.50	10.9	e*
3	Sysmex X	58	98.3	1.7	0.0	4.97	10.5	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	151	98.6	0.7	0.7	4.76	8.2	e
2	Sysmex KX21	92	100.0	0.0	0.0	4.66	6.9	e
3	Sysmex PocH - 100i	179	98.9	1.1	0.0	4.46	8.2	e
4	Sysmex XP 300	567	98.9	0.9	0.2	4.61	7.9	e
5	Mythic	217	96.4	1.8	1.8	4.46	8.7	e
6	Swelab	27	96.3	0.0	3.7	4.80	8.3	e
7	Celltac Alpha (Nihon	52	96.2	1.9	1.9	4.98	9.0	e
8	Samsung HC10	6	83.3	0.0	16.7	4.61	6.8	e
9	Micros 60	53	98.1	0.0	1.9	4.46	8.5	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

Thrombocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	5	100.0	0.0	0.0	168.0	10.1	e*
2	Sysmex X	58	100.0	0.0	0.0	160.3	6.9	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	151	98.6	0.7	0.7	156.2	6.9	e
2	Sysmex KX21	92	98.9	1.1	0.0	173.7	8.4	e
3	Sysmex PocH - 100i	179	99.4	0.6	0.0	169.1	6.6	e
4	Sysmex XP 300	567	97.8	1.1	1.1	176.7	6.8	e
5	Mythic	218	94.5	1.8	3.7	178.5	9.2	e
6	Swelab	27	96.3	0.0	3.7	158.4	11.4	e
7	Celltac Alpha (Nihon	52	96.2	3.8	0.0	154.2	9.3	e
8	Samsung HC10	6	100.0	0.0	0.0	172.5	8.3	e*
9	Micros 60	53	98.1	0.0	1.9	166.1	9.5	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin H2



QUALAB tolerance : 9 %

Hemoglobin H2 (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dymind DP-H10	5	80.0	20.0	0.0	104.0	5.5	e*
2	Microsemi	902	95.7	1.1	3.2	104.4	2.4	e
3	Abx Micros	36	97.2	2.8	0.0	103.5	3.7	e
4	Z3	243	91.8	2.9	5.3	105.1	3.2	e
5	MEK-1303/5	42	95.2	0.0	4.8	107.0	2.0	e

Hematocrit H2



QUALAB tolerance : 9 %

Hematocrit H2 (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dymind DP-H10	5	80.0	0.0	20.0	0.28	3.1	e*
2	Microsemi	902	95.2	1.4	3.4	0.27	3.1	e
3	Abx Micros	36	97.2	0.0	2.8	0.27	3.2	e
4	Z3	244	91.4	2.9	5.7	0.29	4.3	e
5	MEK-1303/5	42	90.5	7.1	2.4	0.33	3.8	e

Leucocytes H2



QUALAB tolerance : 25 %

Leucocytes H2 (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dymind DP-H10	5	100.0	0.0	0.0	4.35	7.0	e*
2	Microsemi	902	98.2	0.7	1.1	4.37	7.3	e
3	Abx Micros	36	100.0	0.0	0.0	4.38	6.7	e
4	Z3	244	99.6	0.0	0.4	4.38	6.0	e
5	MEK-1303/5	42	92.8	4.8	2.4	4.58	8.4	e

Thrombocytes H2



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dymind DP-H10	5	100.0	0.0	0.0	180.0	13.2	e*
2	Microsemi	902	97.0	1.7	1.3	154.5	8.5	e
3	Abx Micros	36	97.2	2.8	0.0	155.5	8.0	e
4	Z3	243	97.6	0.8	1.6	170.2	7.8	e
5	MEK-1303/5	42	97.6	0.0	2.4	159.9	6.1	e

Erythrocytes H2



QUALAB tolerance : 25 %

Erythrocytes H2 (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dymind DP-H10	5	100.0	0.0	0.0	3.42	6.8	e*
2	Microsemi	902	97.6	0.8	1.6	3.33	4.7	e
3	Abx Micros	36	100.0	0.0	0.0	3.31	4.1	e
4	Z3	244	94.7	0.0	5.3	3.30	3.6	e
5	MEK-1303/5	42	95.2	0.0	4.8	3.47	2.6	e

CRP H2



QUALAB tolerance : 21 %

CRP H2 (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dymind DP-H10	4	100.0	0.0	0.0	24.4	9.7	e*
2	Microsemi	883	93.0	3.6	3.4	27.7	10.4	e
3	Abx Micros	11	90.9	0.0	9.1	28.7	5.2	e
4	ABX Micros CRP200	22	95.5	4.5	0.0	27.5	9.8	e
5	Z3	224	91.5	5.4	3.1	26.1	10.9	e
6	MEK-1303/5	37	94.6	0.0	5.4	22.8	7.9	e

Hemoglobin BG



QUALAB tolerance : 9 %

Hemoglobin BG (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	14	100.0	0.0	0.0	121.8	3.1	e

Hematocrit



QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	19	100.0	0.0	0.0	0.35	3.6	e
2	EPOC	16	100.0	0.0	0.0	0.34	2.3	e

Hemoglobin



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	122	100.0	0.0	0.0	118.5	1.3	e
2	Advia	4	100.0	0.0	0.0	123.0	1.4	e
3	Beckman	5	100.0	0.0	0.0	119.0	0.6	e
4	Yumizen/Pentra	13	100.0	0.0	0.0	120.5	1.3	e

Hematocrit



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	122	97.5	2.5	0.0	0.38	3.4	e
2	Advia	4	100.0	0.0	0.0	0.40	0.9	e
3	Beckman	5	100.0	0.0	0.0	0.36	2.9	e*
4	Yumizen/Pentra	13	100.0	0.0	0.0	0.35	2.9	e

Erythrocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	124	100.0	0.0	0.0	3.92	1.6	e
2	Advia	4	100.0	0.0	0.0	4.06	1.8	e
3	Beckman	5	100.0	0.0	0.0	3.95	0.9	e
4	Yumizen/Pentra	13	100.0	0.0	0.0	3.91	2.7	e

Leucocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	123	100.0	0.0	0.0	5.15	6.4	e
2	Advia	4	100.0	0.0	0.0	5.20	3.6	e
3	Beckman	5	100.0	0.0	0.0	5.10	11.6	e*
4	Yumizen/Pentra	13	100.0	0.0	0.0	4.37	10.7	e

Thrombocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	122	97.6	1.6	0.8	154.1	8.5	e
2	Advia	4	100.0	0.0	0.0	156.5	2.1	e
3	Beckman	5	100.0	0.0	0.0	140.4	17.0	a
4	Yumizen/Pentra	13	100.0	0.0	0.0	154.2	6.2	e

Neutrophils



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	123	98.4	1.6	0.0	2.96	7.0	e
2	Advia	4	100.0	0.0	0.0	3.01	2.1	e
3	Beckman	5	100.0	0.0	0.0	2.96	15.8	a
4	Yumizen/Pentra	12	66.7	25.0	8.3	2.05	22.4	e*

Lymphocytes



MQ tolerance : 25 %

Lymphocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	123	100.0	0.0	0.0	1.76	7.1	e
2	Advia	4	100.0	0.0	0.0	1.66	1.2	e
3	Beckman	5	100.0	0.0	0.0	1.55	18.2	a
4	Yumizen/Pentra	12	100.0	0.0	0.0	2.03	12.5	e*

Monocytes



MQ tolerance : 80 %

Monocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	123	99.2	0.8	0.0	0.30	28.3	e
2	Advia	4	100.0	0.0	0.0	0.36	27.2	e*
3	Beckman	5	100.0	0.0	0.0	0.19	56.6	a
4	Yumizen/Pentra	12	83.3	16.7	0.0	0.21	50.6	e*

Eosinophils



MQ tolerance : 80 %
(< 0.13: +/- 0.10 G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	122	96.7	3.3	0.0	0.05	30.8	a
2	Advia	4	100.0	0.0	0.0	0.05	36.1	e*
3	Beckman	5	100.0	0.0	0.0	0.10	46.7	e*
4	Yumizen/Pentra	12	100.0	0.0	0.0	0.03	65.9	e*

Basophiles



MQ tolerance : 80 %
(< 0.13: +/- 0.10 G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	122	93.5	4.9	1.6	0.10	62.2	a
2	Advia	4	100.0	0.0	0.0	0.03	0.0	e
3	Beckman	5	100.0	0.0	0.0	0.05	29.3	e*
4	Yumizen/Pentra	12	100.0	0.0	0.0	0.04	60.2	e*

MCV



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	112	100.0	0.0	0.0	95.8	3.5	e
2	Beckman	4	100.0	0.0	0.0	93.2	3.2	e
3	Yumizen/Pentra	9	100.0	0.0	0.0	88.4	3.3	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

MCH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	113	100.0	0.0	0.0	30.2	1.4	e
2	Beckman	4	100.0	0.0	0.0	30.1	0.5	e
3	Yumizen/Pentra	10	100.0	0.0	0.0	31.0	2.8	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

MCHC



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	114	99.1	0.0	0.9	316	3.6	e
2	Beckman	4	100.0	0.0	0.0	322	2.6	e
3	Yumizen/Pentra	10	100.0	0.0	0.0	348	3.3	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

RDW



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	108	100.0	0.0	0.0	13.0	4.4	e
2	Beckman	4	100.0	0.0	0.0	14.3	4.7	e
3	Yumizen/Pentra	10	100.0	0.0	0.0	13.5	9.7	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Immature Granulocytes



MQ tolerance : 25 %
(< 1.30: +/- 0.10 G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	105	97.1	0.0	2.9	0.03	62.2	e*

Reticulocytes



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	66	98.5	0.0	1.5	40.7	15.4	a
2	Advia	4	100.0	0.0	0.0	27.5	41.0	a
3	Beckman	5	100.0	0.0	0.0	27.5	18.8	a

Hämolyseindex Probe A



MQ tolerance : 30 %
(< 20.000: +/- 8.000 Index (mg/)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	23	100.0	0.0	0.0	17.609	11.3	e
2	Abbott	7	100.0	0.0	0.0	2.000	49.5	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Hämolyseindex Probe B



MQ tolerance : 30 %
(< 20.000: +/- 8.000 Index (mg/)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	23	100.0	0.0	0.0	0.010	0.0	e
2	Abbott	7	100.0	0.0	0.0	0.010	0.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Lipemia index A



MQ tolerance : 30 %

Lipemia index A (Index (mg/)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	88.9	11.1	0.0	9.00	16.9	e*
2	Abbott	6	100.0	0.0	0.0	5.16	11.4	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Lipemia index B



MQ tolerance : 30 %

Lipemia index B (Index (mg/)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	77.8	0.0	22.2	20.00	7.4	e
2	Abbott	6	33.4	33.3	33.3	3.00	29.7	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Icteria Index A



MQ tolerance : 30 %
(< 5.00: +/- 1.50 Index (mg/)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	100.0	0.0	0.0	0.01	0.0	e
2	Abbott	6	100.0	0.0	0.0	0.59	9.2	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Icteria Index B



MQ tolerance : 30 %

Icteria Index B (Index (mg/)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	88.9	11.1	0.0	12.00	14.5	e*
2	Abbott	6	100.0	0.0	0.0	12.11	1.8	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Erythrocyte sedimentation rate 1h



MQ tolerance : 40 %

Erythrocyte sedimentation rate 1h (mm/h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MINI-CUBE	28	85.7	10.7	3.6	13	35.1	a
2	miniiSed	11	90.9	0.0	9.1	1	0.0	a
3	Sarstedt Sedivette	17	94.1	0.0	5.9	12	10.3	a
4	Sarstedt Microvette	4	75.0	25.0	0.0	12	34.5	a
5	BD Seditainer	43	88.4	11.6	0.0	10	25.6	a
6	Other methods	20	95.0	5.0	0.0	12	24.9	a

Erythrocyte sedimentation rate 2h



MQ tolerance : 40 %

Erythrocyte sedimentation rate 2h (mm/2h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sarstedt Sedivette	6	100.0	0.0	0.0	27	6.6	a
2	BD Seditainer	4	75.0	25.0	0.0	31	45.2	a
3	Other methods	4	100.0	0.0	0.0	24	10.7	a

Hemoglobin HS



MQ tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	20	85.0	0.0	15.0	158.2	3.8	e

Hematocrit HS



MQ tolerance : 9 %

Hematocrit HS (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	20	85.0	0.0	15.0	0.4	3.3	e

Erythrocytes HS



MQ tolerance : 25 %

Erythrocytes HS (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	20	85.0	5.0	10.0	4.53	10.2	e

Leucocytes HS



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	20	95.0	0.0	5.0	7.16	8.9	e

Trombocytes HS



MQ tolerance : 25 %

Trombocytes HS (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	20	100.0	0.0	0.0	234.6	4.3	e

Leucoytes BF



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	14	100.0	0.0	0.0	0.060	18.2	a

Erythrocytes BF



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	13	100.0	0.0	0.0	22.427	10.2	e

Total cells (TC)



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	11	100.0	0.0	0.0	0.060	18.0	a

Mononuclear cells (MN)



MQ tolerance : 40 %

Mononuclear cells (MN) (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	14	100.0	0.0	0.0	0.048	10.8	a

Polynuclear cells (PMN)



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	14	92.9	0.0	7.1	0.004	61.8	a

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser	9	88.9	0.0	11.1	23.4	5.0	e
2	Cobas b101	415	99.8	0.0	0.2	22.1	5.0	e
3	Siemens	8	100.0	0.0	0.0	25.4	7.8	e*
4	Cobas	42	100.0	0.0	0.0	24.2	5.0	e
5	Turbidimetry	4	50.0	0.0	50.0	25.2	2.0	a
6	Afinion	1076	99.1	0.1	0.8	24.7	4.7	e
7	NycoCard SingleTest-	50	80.0	6.0	14.0	23.6	11.6	e
8	Quick Read go	86	98.8	0.0	1.2	24.0	8.0	e
9	Eurolyser	55	78.2	3.6	18.2	30.4	10.5	e
10	Fuji Dri-Chem	12	83.3	0.0	16.7	25.4	9.1	e*
11	Piccolo	6	66.6	16.7	16.7	33.6	12.7	e*
12	Celltac chemi	20	100.0	0.0	0.0	23.1	4.8	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	QuikRead (Vollblut)	10	100.0	0.0	0.0	42.3	3.5	e

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Spinit	8	100.0	0.0	0.0	21.2	6.6	e
2	Abbott	14	100.0	0.0	0.0	25.7	2.4	e
3	Beckman	5	80.0	0.0	20.0	23.0	8.9	e*
4	AQT 90 FLEX	5	100.0	0.0	0.0	26.0	4.2	e
5	Spotchem D-Concept	5	100.0	0.0	0.0	26.8	6.4	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

IgG



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	22	100.0	0.0	0.0	10.57	2.9	e
2	Nephelometry	5	100.0	0.0	0.0	11.20	8.9	a
3	Other methods	4	100.0	0.0	0.0	9.76	6.9	e*

IgA



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	20	100.0	0.0	0.0	1.76	2.8	e
2	Nephelometry	7	100.0	0.0	0.0	1.94	6.6	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

IgM



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	22	100.0	0.0	0.0	0.87	4.8	e
2	Nephelometry	7	100.0	0.0	0.0	0.90	6.1	e*

IgE



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	88	12.8	e*
2	Cobas	6	100.0	0.0	0.0	122	5.7	e

Alpha-1-Antitrypsin



MQ tolerance : 25 %

Alpha-1-Antitrypsin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Nephelometry	4	100.0	0.0	0.0	1.03	4.4	e
2	all Participants	9	100.0	0.0	0.0	1.05	7.9	e

Anti-Streptolysin-Antibodies



MQ tolerance : 25 %

Anti-Streptolysin-Antibodies (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	11	100.0	0.0	0.0	112	8.4	e
2	Other methods	6	83.3	0.0	16.7	84	1.7	e

Complement C3



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	20	100.0	0.0	0.0	1.30	5.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Complement C4



QUALAB tolerance : 15 %

Complement C4 (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	6	100.0	0.0	0.0	0.25	4.6	e*
2	Other methods	15	100.0	0.0	0.0	0.25	8.9	a

Haptoglobin



MQ tolerance : 25 %

Haptoglobin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	29	100.0	0.0	0.0	1.19	3.2	e

Transferrin



MQ tolerance : 25 %

Transferrin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	37	100.0	0.0	0.0	1.90	2.3	e

Beta-2 microglobuline



MQ tolerance : 25 %

Beta-2 microglobuline (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	12	100.0	0.0	0.0	1.38	6.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Rheumatoid factor



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	7	100.0	0.0	0.0	29.0	2.3	e
2	Other methods	11	100.0	0.0	0.0	26.9	4.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Ceruloplasmin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens	9	100.0	0.0	0.0	261.00	5.2	e
2	Other methods	4	100.0	0.0	0.0	191.50	2.4	e

Prealbumin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	19	100.0	0.0	0.0	175.26	5.5	e

Soluble transferrin receptor



MQ tolerance : 25 %

Soluble transferrin receptor (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	2.2	2.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

free light chain kappa



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	N Latex	6	100.0	0.0	0.0	9.39	3.4	e
2	Freelite	13	100.0	0.0	0.0	18.69	5.8	e

free light chain lambda



QUALAB tolerance : 20 %

free light chain lambda (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	N Latex	6	100.0	0.0	0.0	10.40	5.9	e*
2	Freelite	13	100.0	0.0	0.0	15.35	6.5	e

IgE peanut qn



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	78.6	21.4	0.0	51.11	19.9	e*

IgE birch qn



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	15	86.7	13.3	0.0	11.51	16.9	e*

IgE cat qn



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	92.9	7.1	0.0	6.96	14.8	e*

IgE total



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	521	12.0	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

IgE sx1 qn



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	10	80.0	0.0	20.0	15.15	13.0	e*

IgE fx5 qn



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	10	100.0	0.0	0.0	50.66	14.3	e*

IgE rx1qn



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	6.60	17.0	a

IgE rx2 qn



MQ tolerance : 30 %

IgE rx2 qn (kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	7.77	18.5	e*

IgE D. pteronyssinus qn



QUALAB tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

IgE D. pteronyssinus qn (kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	12	100.0	0.0	0.0	1.39	11.9	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

CRP HS



QUALAB tolerance : 21 %
(< 10.00: +/- 2.00 mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	10	100.0	0.0	0.0	5.37	10.5	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Lipoprotein (a)



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	50	2.8	e
2	Others	6	100.0	0.0	0.0	65	10.2	e*

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	193	93.8	2.1	4.1	29.7	9.0	e

Anti deam. Gliadin IgG



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Phadia	8	100.0	0.0	0.0	26.00	10.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti deam. Gliadin IgA



MQ tolerance : 30 %

Anti deam. Gliadin IgA (U/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Phadia	7	100.0	0.0	0.0	32.00	15.6	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti tTG IgG



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	4	100.0	0.0	0.0	135.00	8.1	e*

Anti tTG IgA



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	8	75.0	0.0	25.0	128.00	0.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

CRP Lumira



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	11	81.8	18.2	0.0	12.3	16.0	a

Albumine



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	11	100.0	0.0	0.0	35.6	1.4	e
2	Beckman	4	100.0	0.0	0.0	37.0	1.5	e
3	Roche	35	100.0	0.0	0.0	38.3	3.0	e
4	Siemens	5	100.0	0.0	0.0	36.0	7.3	e*
5	Autolyser	8	100.0	0.0	0.0	37.2	3.7	e
6	Selectra Pro	10	100.0	0.0	0.0	36.0	2.1	e
7	Fuji Dri-Chem	247	98.4	1.2	0.4	46.1	4.4	e
8	Spotchem D-Concept	236	95.4	3.8	0.8	44.7	5.9	e
9	Spotchem SP-4430	29	96.6	3.4	0.0	42.6	4.6	e
10	Piccolo	59	98.3	0.0	1.7	39.3	4.1	e
11	Skyla	4	100.0	0.0	0.0	39.5	2.4	e
12	Hitachi S40/M40	5	80.0	0.0	20.0	31.0	1.7	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Alkaline phosphatase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	96	3.1	e
2	Beckman	6	100.0	0.0	0.0	96	5.4	e*
3	Roche	35	100.0	0.0	0.0	85	4.5	e
4	Siemens	7	100.0	0.0	0.0	87	5.2	e
5	Autolyser	21	100.0	0.0	0.0	91	6.8	e
6	Selectra Pro	13	92.3	7.7	0.0	99	7.5	e
7	Fuji Dri-Chem	1017	97.5	2.0	0.5	100	6.9	e
8	Spotchem D-Concept	555	98.4	0.5	1.1	85	6.0	e
9	Spotchem SP-4430	80	97.5	2.5	0.0	81	8.2	e
10	Piccolo	50	100.0	0.0	0.0	104	6.4	e
11	Skyla	5	100.0	0.0	0.0	101	4.9	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Amylase



QUALAB tolerance : 18 %
(< 50: +/- 9 U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	10	90.0	0.0	10.0	121	2.8	e
2	Beckman	4	100.0	0.0	0.0	147	5.7	e*
3	Roche	14	100.0	0.0	0.0	136	2.5	e
4	Autolyser	8	100.0	0.0	0.0	118	5.6	e
5	Selectra Pro	9	100.0	0.0	0.0	180	4.3	e
6	Fuji Dri-Chem	734	99.5	0.4	0.1	95	4.4	e
7	Spotchem D-Concept	400	96.0	3.5	0.5	63	7.7	e
8	Spotchem SP-4430	63	85.7	1.6	12.7	21	18.7	e*
9	Piccolo	55	100.0	0.0	0.0	123	3.1	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Pancreatic amylase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	100.0	0.0	0.0	97	2.5	e
2	Roche	17	100.0	0.0	0.0	112	2.1	e
3	Siemens	4	100.0	0.0	0.0	117	15.0	e*
4	Autolyser	10	100.0	0.0	0.0	103	4.5	e

Bilirubin



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	92.9	7.1	0.0	22.3	8.5	e*
2	Beckman	6	100.0	0.0	0.0	29.4	8.9	a
3	Roche	34	97.1	2.9	0.0	21.5	6.7	e
4	Siemens	7	85.7	14.3	0.0	28.0	10.4	e*
5	Autolyser	18	88.8	5.6	5.6	22.0	9.7	e*
6	Selectra Pro	15	73.3	6.7	20.0	18.8	11.0	e*
7	Fuji Dri-Chem	829	92.3	4.9	2.8	26.2	8.9	e
8	Spotchem D-Concept	442	95.5	2.5	2.0	27.9	7.8	e
9	Spotchem SP-4430	75	90.7	5.3	4.0	26.4	8.8	e
10	Piccolo	57	96.5	0.0	3.5	22.3	9.0	e
11	Skyla	5	60.0	40.0	0.0	26.6	15.7	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin direct



MQ tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser	12	91.7	0.0	8.3	15.9	8.3	e*
2	Fuji Dri-Chem	23	78.3	13.0	8.7	12.8	11.6	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium



QUALAB tolerance : 9 %
(< 2.00: +/- 0.18 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	17	100.0	0.0	0.0	2.03	2.9	e
2	Beckman	5	100.0	0.0	0.0	2.02	2.2	e
3	Roche	37	100.0	0.0	0.0	2.00	1.7	e
4	Siemens	5	100.0	0.0	0.0	2.03	3.8	e*
5	Autolyser	9	100.0	0.0	0.0	2.10	4.6	a
6	Fuji Dri-Chem	265	97.8	1.1	1.1	2.03	4.1	e
7	Spotchem D-Concept	75	90.6	6.7	2.7	1.43	6.5	e
8	Spotchem SP-4430	12	91.7	0.0	8.3	1.91	2.0	e
9	Piccolo	50	98.0	0.0	2.0	2.00	3.2	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium ISE



MQ tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	11	90.9	9.1	0.0	0.75	4.3	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Chloride



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	17	100.0	0.0	0.0	105	1.9	e
2	Beckman	5	80.0	20.0	0.0	102	3.4	e*
3	Roche	27	96.3	3.7	0.0	103	1.7	e
4	Siemens	5	100.0	0.0	0.0	105	0.9	e
5	Fuji Dri-Chem	937	98.4	0.9	0.7	112	1.7	e
6	Spotchem D-Concept	423	98.6	0.9	0.5	113	1.7	e
7	Spotchem EL-SE 1520	61	93.5	1.6	4.9	118	2.6	e
8	Piccolo	27	100.0	0.0	0.0	104	2.0	e
9	Exias	21	100.0	0.0	0.0	106	1.5	e
10	iStat Chem8	11	100.0	0.0	0.0	111	0.9	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol total



QUALAB tolerance : 10 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	18	100.0	0.0	0.0	4.22	2.7	e
2	Beckman	4	100.0	0.0	0.0	4.18	6.9	e*
3	Roche	29	100.0	0.0	0.0	4.14	2.2	e
4	Siemens	4	100.0	0.0	0.0	4.29	1.9	e
5	Autolyser	21	100.0	0.0	0.0	4.21	4.2	e
6	Selectra Pro	13	100.0	0.0	0.0	4.31	3.2	e
7	Fuji Dri-Chem	970	96.3	1.8	1.9	3.91	3.9	e
8	Spotchem D-Concept	470	96.8	1.3	1.9	4.11	3.5	e
9	Spotchem SP-4430	80	96.2	1.3	2.5	3.93	3.7	e
10	Piccolo	24	100.0	0.0	0.0	4.19	2.2	e
11	Reflotron	4	75.0	25.0	0.0	3.94	8.3	e*
12	Cholestech LDX	265	94.7	1.9	3.4	3.88	4.1	e
13	Other methods	4	100.0	0.0	0.0	3.44	1.5	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterin HDL



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	100.0	0.0	0.0	0.97	4.1	e
2	Beckman	6	100.0	0.0	0.0	1.21	5.5	e
3	Roche	27	100.0	0.0	0.0	0.93	4.2	e
4	Dimension	4	100.0	0.0	0.0	1.71	5.9	e*
5	Autolyser	21	95.2	4.8	0.0	1.72	11.4	e
6	Selectra Pro	13	84.6	0.0	15.4	1.65	11.2	e*
7	Fuji Dri-Chem	938	98.6	0.2	1.2	1.50	4.3	e
8	Spotchem D-Concept	454	95.2	3.5	1.3	0.73	9.4	e
9	Spotchem SP-4430	73	90.5	6.8	2.7	0.69	9.8	e
10	Piccolo	23	95.7	0.0	4.3	1.17	10.3	e
11	Cholestech LDX	265	93.2	4.2	2.6	1.04	9.7	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatine kinase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	176	1.8	e
2	Beckman	5	100.0	0.0	0.0	178	3.2	e
3	Roche	32	100.0	0.0	0.0	169	1.7	e
4	Siemens	7	85.7	0.0	14.3	167	2.1	e
5	Autolyser	17	94.1	0.0	5.9	192	3.5	e
6	Selectra Pro	8	100.0	0.0	0.0	168	3.9	e
7	Fuji Dri-Chem	663	98.0	1.1	0.9	182	4.9	e
8	Spotchem D-Concept	318	98.1	0.6	1.3	149	6.5	e
9	Spotchem SP-4430	39	87.2	7.7	5.1	159	9.5	e
10	Piccolo	19	94.7	0.0	5.3	172	6.9	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol LDL



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	2.1	4.7	e
2	Beckman	5	100.0	0.0	0.0	2.7	5.8	e*
3	Roche, Cobas	17	100.0	0.0	0.0	2.9	3.6	e
4	Autolyser	10	90.0	0.0	10.0	2.9	7.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Iron



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	100.0	0.0	0.0	36	2.6	e
2	Roche	20	100.0	0.0	0.0	36	0.9	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Gamma-glutamyltransferase



QUALAB tolerance : 18 %
(< 40: +/- 8 U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	44	6.1	e
2	Beckman	6	83.3	16.7	0.0	41	8.4	e*
3	Cobas	36	97.2	2.8	0.0	38	7.2	e
4	Siemens	7	100.0	0.0	0.0	45	6.7	e*
5	Autolyser	21	95.2	0.0	4.8	39	2.7	e
6	Selectra Pro	14	92.9	7.1	0.0	34	13.5	e*
7	Fuji Dri-Chem	1130	99.6	0.0	0.4	47	4.9	e
8	Spotchem D-Concept	623	98.5	0.5	1.0	44	6.9	e
9	Spotchem SP-4430	129	95.3	3.9	0.8	50	8.6	e
10	Piccolo	60	100.0	0.0	0.0	36	5.5	e
11	Skyla	5	100.0	0.0	0.0	36	5.3	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	100.0	0.0	0.0	6.3	1.2	e
2	Beckman	6	83.3	16.7	0.0	6.3	6.8	e*
3	Roche	38	100.0	0.0	0.0	6.3	2.0	e
4	Siemens	6	83.3	0.0	16.7	6.4	1.1	e
5	Autolyser	19	94.7	0.0	5.3	6.3	2.8	e
6	Selectra Pro	15	86.7	13.3	0.0	6.5	5.3	e*
7	Fuji Dri-Chem	1074	98.9	0.3	0.8	6.0	2.5	e
8	Spotchem D-Concept	584	96.7	2.4	0.9	6.2	4.1	e
9	Spotchem SP-4430	107	96.3	0.9	2.8	6.6	4.3	e
10	Piccolo	71	100.0	0.0	0.0	6.4	1.3	e
11	Cholestech LDX	260	95.0	2.3	2.7	6.0	3.7	e
12	iStat Chem8	12	100.0	0.0	0.0	5.8	2.0	e
13	Cobas Pulse	54	94.4	3.7	1.9	5.8	3.5	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Accu-Chek Instant	127	96.8	0.8	2.4	6.0	3.4	e
2	Accu-Chek Aviva	102	90.2	2.9	6.9	7.0	3.7	e
3	Accu-Chek Inform 2	896	98.2	1.0	0.8	7.4	3.1	e
4	Accu-Check Guide	341	97.6	0.6	1.8	5.9	3.1	e
5	Contour XT	1393	96.5	2.6	0.9	6.3	3.6	e
6	Skyla	5	100.0	0.0	0.0	6.5	1.7	e
7	Statstrip/Xpress	87	100.0	0.0	0.0	6.0	3.0	e
8	Glucocard	6	66.7	33.3	0.0	8.7	6.9	e*
9	Hemocue 201+ P-equiv	148	96.6	0.0	3.4	7.9	2.8	e
10	Hemocue 201RT P-equi	131	96.1	0.8	3.1	7.9	2.7	e
11	Contour NEXT	48	93.7	6.3	0.0	6.0	3.8	e

11 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose B



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OneTouch Verio	29	93.2	3.4	3.4	6.2	4.9	e
2	Contour 2 (5s)	8	100.0	0.0	0.0	5.0	3.8	e*
3	Healthpro	21	90.5	0.0	9.5	10.8	4.7	e
4	Mylife UNIO	345	96.9	1.7	1.4	7.2	3.7	e
5	mylife Pura	89	84.3	10.1	5.6	7.2	6.1	e
6	Alpha Check	25	88.0	4.0	8.0	9.8	4.2	e

Uric Acid



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	17	100.0	0.0	0.0	274	2.8	e
2	Beckman	6	100.0	0.0	0.0	288	4.3	e*
3	Roche	33	100.0	0.0	0.0	272	2.3	e
4	Siemens	5	100.0	0.0	0.0	287	2.6	e
5	Autolyser	18	100.0	0.0	0.0	292	3.5	e
6	Selectra Pro	15	100.0	0.0	0.0	268	5.1	e
7	Fuji Dri-Chem	1047	98.8	0.4	0.8	307	2.7	e
8	Spotchem D-Concept	587	99.3	0.2	0.5	270	4.1	e
9	Spotchem SP-4430	103	92.2	3.9	3.9	231	5.8	e
10	Piccolo	36	94.4	0.0	5.6	209	5.5	e
11	Skyla	5	100.0	0.0	0.0	281	3.3	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Urea



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	7.9	3.8	e
2	Beckman	6	100.0	0.0	0.0	7.6	3.9	e
3	Roche	33	97.0	3.0	0.0	7.3	5.2	e
4	Siemens	7	100.0	0.0	0.0	7.8	6.2	e*
5	Autolyser	16	93.7	0.0	6.3	8.1	6.1	e
6	Selectra Pro	11	100.0	0.0	0.0	7.8	5.6	e
7	Fuji Dri-Chem	617	98.9	0.0	1.1	7.8	2.5	e
8	Spotchem D-Concept	329	93.6	4.9	1.5	7.1	7.4	e
9	Spotchem SP-4430	55	94.6	3.6	1.8	7.3	7.4	e
10	Piccolo	65	98.5	0.0	1.5	6.8	3.0	e
11	Skyla	5	100.0	0.0	0.0	7.8	2.7	e
12	iStat Chem8	9	100.0	0.0	0.0	10.1	2.8	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Potassium



QUALAB tolerance : 6 %
(< 3.30: +/- 0.20 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	17	100.0	0.0	0.0	3.08	1.1	e
2	Beckman	6	100.0	0.0	0.0	3.08	3.3	e*
3	Roche	36	100.0	0.0	0.0	3.08	1.5	e
4	Siemens	5	100.0	0.0	0.0	3.00	1.5	e
5	Autolyser	16	75.0	12.5	12.5	2.92	5.3	e*
6	Fuji Dri-Chem	1100	99.5	0.3	0.2	2.99	1.3	e
7	Spotchem D-Concept	543	96.7	2.2	1.1	2.80	2.0	e
8	Spotchem EL-SE 1520	79	93.7	6.3	0.0	2.80	2.4	e
9	Piccolo	41	48.8	31.7	19.5	3.20	5.6	e*
10	iStat Chem8	15	100.0	0.0	0.0	3.01	0.9	e
11	Exias	23	100.0	0.0	0.0	3.08	1.1	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	183	3.3	e
2	Beckman	6	100.0	0.0	0.0	187	6.5	e*
3	Roche	35	100.0	0.0	0.0	184	2.9	e
4	Siemens	7	100.0	0.0	0.0	185	2.8	e
5	Enzymatic	4	100.0	0.0	0.0	183	6.3	e*
6	Autolyser	21	100.0	0.0	0.0	176	3.9	e
7	Selectra Pro	15	100.0	0.0	0.0	178	6.9	e
8	Fuji Dri-Chem	1162	99.0	0.3	0.7	166	4.4	e
9	Spotchem D-Concept	641	98.7	0.2	1.1	89	5.2	e
10	Spotchem SP-4430	148	98.0	0.0	2.0	86	5.1	e
11	Piccolo	67	98.5	0.0	1.5	185	5.3	e
12	Skyla	5	100.0	0.0	0.0	178	7.1	e*
13	Reflotron	6	66.6	16.7	16.7	201	10.8	e*
14	EPOC	11	72.7	0.0	27.3	178	9.2	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Creatinine E



QUALAB tolerance : 18 %

Creatinine E (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	46	97.8	0.0	2.2	181	2.7	e
2	ABL700/800	15	100.0	0.0	0.0	180	7.7	e

eGFR CKD-EPI



MQ tolerance : 30 %

eGFR CKD-EPI ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	56	98.2	0.0	1.8	30	6.3	e
2	Fuji Dri-Chem	393	95.9	1.0	3.1	34	7.0	e
3	Spotchem	264	91.7	3.4	4.9	75	10.3	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

eGFR Cockcroft-Gault



MQ tolerance : 30 %

eGFR Cockcroft-Gault ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	33	84.9	3.0	12.1	38	10.6	e
2	Spotchem	16	93.7	0.0	6.3	72	4.5	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

LDH



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	17	100.0	0.0	0.0	129	5.3	e
2	Beckman	5	100.0	0.0	0.0	139	8.4	e*
3	Roche	34	100.0	0.0	0.0	138	2.2	e
4	Siemens	4	100.0	0.0	0.0	139	8.9	e*
5	Autolyser	7	100.0	0.0	0.0	137	6.6	e*
6	Fuji Dri-Chem	113	96.4	0.9	2.7	119	5.0	e
7	Spotchem D-Concept	42	78.6	14.3	7.1	64	12.6	e
8	Spotchem SP-4430	12	91.7	8.3	0.0	75	10.5	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Magnesium



QUALAB tolerance : 12 %
(< 0.70: +/- 0.09 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	100.0	0.0	0.0	0.66	3.2	e
2	Beckman	4	100.0	0.0	0.0	0.67	1.9	e
3	Roche	28	89.3	10.7	0.0	0.69	6.4	e
4	Siemens	4	100.0	0.0	0.0	0.68	7.2	a
5	Fuji Dri-Chem	74	93.2	5.4	1.4	0.72	4.6	e
6	Spotchem D-Concept	39	100.0	0.0	0.0	0.51	4.6	e
7	Spotchem SP-4430	4	100.0	0.0	0.0	0.56	1.5	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser	6	100.0	0.0	0.0	148	1.4	e
2	Abbott	18	100.0	0.0	0.0	143	1.1	e
3	Beckman	6	83.3	16.7	0.0	142	3.3	e*
4	Roche	36	100.0	0.0	0.0	143	1.3	e
5	Siemens	5	100.0	0.0	0.0	144	0.9	e
6	Fuji Dri-Chem	1017	99.2	0.3	0.5	145	1.1	e
7	Spotchem D-Concept	469	99.6	0.2	0.2	137	1.2	e
8	Spotchem EL-SE 1520	67	98.5	1.5	0.0	137	1.4	e
9	Piccolo	37	100.0	0.0	0.0	140	1.4	e
10	Exias	23	100.0	0.0	0.0	143	1.0	e
11	iStat Chem8	15	100.0	0.0	0.0	142	0.7	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Phosphate



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	100.0	0.0	0.0	1.17	5.4	e
2	Beckman	4	100.0	0.0	0.0	1.17	5.0	e*
3	Roche	33	100.0	0.0	0.0	1.14	3.5	e
4	Siemens	4	100.0	0.0	0.0	1.23	4.8	e*
5	Fuji Dri-Chem	73	90.5	2.7	6.8	1.21	6.6	e
6	Spotchem D-Concept	14	85.8	7.1	7.1	1.18	7.7	e*
7	Piccolo	4	100.0	0.0	0.0	1.52	1.0	e

10 additional results were submitted but not published because the method groups were too small. (< results per group)

Protein total



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	93.3	6.7	0.0	57.7	4.1	e
2	Beckman	4	100.0	0.0	0.0	59.1	3.2	e*
3	Roche	30	93.3	0.0	6.7	57.7	2.3	e
4	Siemens	5	100.0	0.0	0.0	60.0	2.2	e
5	Selectra Pro	8	100.0	0.0	0.0	58.0	2.3	e
6	Fuji Dri-Chem	185	98.9	0.0	1.1	56.0	3.3	e
7	Spotchem D-Concept	183	96.2	2.7	1.1	59.0	5.6	e
8	Spotchem SP-4430	26	92.3	0.0	7.7	61.4	3.1	e
9	Piccolo	49	100.0	0.0	0.0	58.3	1.7	e
10	Skyla	5	100.0	0.0	0.0	62.0	2.7	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Aspartate aminotransferase



QUALAB tolerance : 18 %

Aspartate aminotransferase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	17	100.0	0.0	0.0	75	4.1	e
2	Beckman	5	100.0	0.0	0.0	75	7.5	e*
3	Roche	37	100.0	0.0	0.0	73	4.4	e
4	Siemens	5	100.0	0.0	0.0	72	3.0	e
5	Autolyser	21	95.2	0.0	4.8	65	5.0	e
6	Selectra Pro	15	100.0	0.0	0.0	78	6.3	e
7	Fuji Dri-Chem	1139	98.9	0.4	0.7	71	4.3	e
8	Spotchem D-Concept	626	99.3	0.2	0.5	47	5.0	e
9	Spotchem SP-4430	139	98.6	0.7	0.7	48	5.6	e
10	Piccolo	73	100.0	0.0	0.0	63	4.7	e
11	Skyla	5	100.0	0.0	0.0	66	5.2	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Alanine aminotransferase



QUALAB tolerance : 18 %

Alanine aminotransferase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	53	5.6	e
2	Beckman	6	100.0	0.0	0.0	60	6.4	e*
3	Roche	37	100.0	0.0	0.0	60	4.2	e
4	Siemens	7	85.7	14.3	0.0	64	8.9	e*
5	Autolyser	21	95.2	0.0	4.8	60	5.3	e
6	Selectra Pro	15	93.3	0.0	6.7	69	8.9	e*
7	Fuji Dri-Chem	1157	98.5	0.5	1.0	63	5.0	e
8	Spotchem D-Concept	631	98.9	0.5	0.6	40	5.8	e
9	Spotchem SP-4430	139	97.2	1.4	1.4	46	7.3	e
10	Piccolo	71	98.6	0.0	1.4	54	5.8	e
11	Skyla	5	100.0	0.0	0.0	63	4.3	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Triglycerides



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	2.24	2.6	e
2	Beckman	5	100.0	0.0	0.0	2.30	4.9	e*
3	Roche	29	100.0	0.0	0.0	2.33	1.6	e
4	Siemens	6	100.0	0.0	0.0	2.28	4.5	e
5	Autolyser	21	95.2	4.8	0.0	2.21	7.2	e
6	Selectra Pro	12	100.0	0.0	0.0	2.40	5.7	e
7	Fuji Dri-Chem	957	98.6	1.0	0.4	2.83	5.4	e
8	Spotchem D-Concept	454	95.8	0.9	3.3	1.39	5.3	e
9	Spotchem SP-4430	75	93.4	1.3	5.3	1.36	5.1	e
10	Piccolo	21	100.0	0.0	0.0	2.63	3.1	e
11	Cholestech LDX	264	98.5	1.1	0.4	2.20	4.9	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Lithium



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	1.08	4.7	e*
2	Roche	14	100.0	0.0	0.0	1.15	3.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Lactate



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	7	100.0	0.0	0.0	2.48	1.2	e
2	Roche	17	100.0	0.0	0.0	2.43	3.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

HbA1c sample A



QUALAB tolerance : 9 %

HbA1c sample A (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	5	100.0	0.0	0.0	5.9	2.4	e
2	Roche, Cobas	19	100.0	0.0	0.0	5.9	4.1	e
3	HPLC	11	100.0	0.0	0.0	5.8	2.5	e
4	Afinion	522	99.0	0.4	0.6	5.8	2.5	e
5	Cobas b101	210	98.6	1.4	0.0	5.5	3.5	e
6	DCA2000/Vantage	138	96.4	2.2	1.4	5.9	3.6	e
7	Celltac chemi	20	100.0	0.0	0.0	5.4	4.2	e
8	NycoCard	7	71.4	0.0	28.6	5.9	3.7	c
9	Eurolyser	6	83.3	16.7	0.0	5.8	5.7	e*
10	A1c Now	219	91.3	5.5	3.2	5.4	4.4	e
11	AFIAS	127	78.8	15.7	5.5	5.1	6.0	e
12	Others	19	100.0	0.0	0.0	5.8	4.1	e
13	Quick Read go	4	75.0	0.0	25.0	5.9	1.0	c

2 additional results were submitted but not published because the method groups were too small. (< results per group)

HbA1c sample B



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	5.3	2.4	e*
2	Roche, Cobas	18	100.0	0.0	0.0	5.4	3.8	e
3	HPLC	11	100.0	0.0	0.0	5.4	3.3	e
4	Afinion	731	99.5	0.1	0.4	5.3	2.5	e
5	Cobas b101	207	98.1	1.9	0.0	5.1	3.2	e
6	DCA2000/Vantage	189	95.3	4.2	0.5	5.5	3.9	e
7	Celltac chemi	22	100.0	0.0	0.0	5.0	4.3	e
8	NycoCard	5	80.0	20.0	0.0	5.5	5.7	c
9	Eurolyser	5	100.0	0.0	0.0	5.6	5.4	e*
10	A1c Now	8	100.0	0.0	0.0	5.5	4.8	c
11	AFIAS	184	81.6	9.2	9.2	5.0	5.5	e
12	Others	13	84.6	0.0	15.4	5.4	2.3	e
13	Quick Read go	5	100.0	0.0	0.0	5.5	3.8	c

3 additional results were submitted but not published because the method groups were too small. (< results per group)

pCO2



QUALAB tolerance : 12 %

pCO2 (kPa)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	109	99.1	0.0	0.9	5.36	2.7	e
2	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	6.02	5.5	e*
3	ABL90 FLEX / PLUS	117	99.1	0.9	0.0	5.53	2.1	e
4	Cobas b 123	16	100.0	0.0	0.0	5.59	1.9	e
5	Cobas b 221	5	100.0	0.0	0.0	5.93	3.2	e
6	GEM	8	100.0	0.0	0.0	5.70	2.3	e
7	iStat	51	96.1	3.9	0.0	4.92	4.2	e
8	EPOC	53	96.2	0.0	3.8	5.21	2.8	e
9	IL	4	100.0	0.0	0.0	5.60	3.1	e*

8 additional results were submitted but not published because the method groups were too small. (< results per group)

pO2



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	108	97.2	0.0	2.8	14.63	3.9	e
2	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	13.43	7.6	e*
3	ABL90 FLEX / PLUS	118	95.8	3.4	0.8	13.48	5.5	e
4	Cobas b 123	17	94.1	5.9	0.0	14.08	6.1	e
5	GEM	8	87.5	0.0	12.5	14.20	1.7	e
6	iStat	48	95.8	2.1	2.1	15.57	6.0	e
7	EPOC	53	92.4	3.8	3.8	14.48	7.2	e
8	IL	4	100.0	0.0	0.0	14.20	1.8	e

10 additional results were submitted but not published because the method groups were too small. (< results per group)

pH



QUALAB tolerance : 1 %

pH ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	108	99.1	0.0	0.9	7.39	0.1	e
2	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	7.38	0.1	e
3	ABL90 FLEX / PLUS	118	100.0	0.0	0.0	7.40	0.1	e
4	Cobas b 123	17	100.0	0.0	0.0	7.41	0.1	e
5	Cobas b 221	5	100.0	0.0	0.0	7.40	0.2	e
6	GEM	8	100.0	0.0	0.0	7.40	0.1	e
7	iStat	53	100.0	0.0	0.0	7.43	0.1	e
8	EPOC	53	98.1	1.9	0.0	7.38	0.2	e
9	IL	4	100.0	0.0	0.0	7.42	0.3	e*

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose BG



QUALAB tolerance : 9 %

Glucose BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	5	100.0	0.0	0.0	5.8	1.0	e
2	Cobas b 123	10	100.0	0.0	0.0	5.5	2.6	e
3	iStat	10	100.0	0.0	0.0	5.5	1.8	e
4	EPOC	42	97.6	0.0	2.4	5.5	3.0	e
5	ABL700/800	99	100.0	0.0	0.0	5.7	2.1	e
6	ABL90 FLEX / PLUS	104	100.0	0.0	0.0	5.6	1.6	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin BG



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	101	96.0	0.0	4.0	128.9	1.7	e
2	ABL90 FLEX / PLUS	106	100.0	0.0	0.0	129.3	0.5	e
3	ABL80 FLEX CO-OX / O	5	100.0	0.0	0.0	125.0	2.5	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Potassium BG



QUALAB tolerance : 6 %

Potassium BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	6	100.0	0.0	0.0	3.8	1.3	e
2	Cobas b 123	18	100.0	0.0	0.0	3.8	0.7	e
3	iStat	18	94.4	0.0	5.6	3.8	1.5	e
4	EPOC	43	100.0	0.0	0.0	3.8	1.4	e
5	ABL700/800	100	99.0	0.0	1.0	3.8	1.6	e
6	ABL90 FLEX / PLUS	110	100.0	0.0	0.0	3.7	1.0	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium BG



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	7	85.7	0.0	14.3	137.0	0.6	e
2	Cobas b 123	18	100.0	0.0	0.0	138.0	0.6	e
3	iStat	18	94.4	0.0	5.6	142.4	0.6	e
4	EPOC	42	100.0	0.0	0.0	140.6	0.6	e
5	ABL700/800	99	100.0	0.0	0.0	140.7	1.0	e
6	ABL90 FLEX / PLUS	109	100.0	0.0	0.0	141.6	0.4	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Chlorid-BG



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b 123	11	100.0	0.0	0.0	100.4	0.9	e
2	EPOC	19	100.0	0.0	0.0	100.8	1.5	e
3	ABL700/800	95	100.0	0.0	0.0	98.8	1.7	e
4	ABL90 FLEX / PLUS	106	100.0	0.0	0.0	97.3	0.5	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium-BG



MQ tolerance : 12 %
(< 2.00: +/- 0.24 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	6	100.0	0.0	0.0	0.44	2.0	e
2	Cobas b123	10	100.0	0.0	0.0	0.37	10.6	e*
3	Roche, Cobas	4	100.0	0.0	0.0	0.41	20.3	e*
4	iStat	15	100.0	0.0	0.0	0.48	1.3	e
5	EPOC	39	97.4	0.0	2.6	0.53	3.6	e
6	ABL700/800	99	99.0	0.0	1.0	0.53	3.7	e
7	ABL90 FLEX / PLUS	107	100.0	0.0	0.0	0.52	1.0	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

FHHb



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL90 FLEX / PLUS	18	100.0	0.0	0.0	2.911	2.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Lactate-BG



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	6	100.0	0.0	0.0	1.80	2.2	e
2	Cobas b123	9	100.0	0.0	0.0	1.90	2.6	e
3	IL	4	100.0	0.0	0.0	1.70	5.7	e*
4	EPOC	41	97.6	0.0	2.4	1.74	2.6	e
5	iStat	19	100.0	0.0	0.0	1.60	1.7	e
6	ABL700/800	103	100.0	0.0	0.0	1.70	4.4	e
7	ABL90 FLEX / PLUS	112	98.2	0.9	0.9	1.61	3.2	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

sO2 OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	25	96.0	0.0	4.0	98.875	0.3	e
2	ABL700/800	90	100.0	0.0	0.0	96.728	2.0	e
3	ABL90 FLEX / PLUS	96	100.0	0.0	0.0	96.912	0.2	e
4	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	96.950	0.2	e

FO2Hb OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	88	98.9	0.0	1.1	92.233	0.1	e
2	ABL90 FLEX / PLUS	97	100.0	0.0	0.0	92.256	1.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FCOHb OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	89	94.4	4.5	1.1	2.873	9.9	e
2	ABL90 FLEX / PLUS	97	98.0	1.0	1.0	2.894	5.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FMetHb OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	89	100.0	0.0	0.0	1.969	4.2	e
2	ABL90 FLEX / PLUS	97	100.0	0.0	0.0	2.020	3.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FHbF OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL90 FLEX / PLUS	36	100.0	0.0	0.0	79.139	2.2	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin OR



QUALAB tolerance : 18 %

Bilirubin OR (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	5	100.0	0.0	0.0	295.0	2.0	e
2	ABL90 FLEX / PLUS	34	100.0	0.0	0.0	298.2	0.5	e

Troponin I



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Pathfast	26	92.4	3.8	3.8	7945.0	11.2	e
2	Vidas	13	92.3	7.7	0.0	14760.9	13.3	e*
3	Abbott	12	91.7	8.3	0.0	1760.2	9.6	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Troponin T



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas hs	11	100.0	0.0	0.0	791.80	5.8	e
2	Cobas hs STAT	15	100.0	0.0	0.0	793.80	5.1	e

Myoglobin



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	6	100.0	0.0	0.0	115.0	5.5	e
2	Abbott	5	100.0	0.0	0.0	169.6	1.6	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

CK-MB mass



MQ tolerance : 40 %

CK-MB mass (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	21.8	7.0	e
2	Cobas E / Elecsys	10	100.0	0.0	0.0	24.0	2.0	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

BNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	6	83.3	16.7	0.0	1027.3	14.2	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

NT-proBNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Pathfast	19	94.7	0.0	5.3	3483.8	6.4	e
2	AQT 90 FLEX	4	75.0	25.0	0.0	2585.0	19.6	e*
3	VIDAS	9	100.0	0.0	0.0	1111.0	4.9	e
4	Cobas E / Elecsys	23	100.0	0.0	0.0	1147.2	4.4	e
5	Abbott	9	100.0	0.0	0.0	1300.0	4.5	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

TSH



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	30	100.0	0.0	0.0	6.24	4.3	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	5.26	4.4	e*
3	Abbott	13	100.0	0.0	0.0	4.76	6.2	e
4	VIDAS	15	100.0	0.0	0.0	6.71	4.9	e
5	Dimension	5	100.0	0.0	0.0	5.86	6.0	e*
6	AFIAS	17	64.7	11.8	23.5	9.10	10.7	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

T3



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	2.8	4.5	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

T4



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	5	100.0	0.0	0.0	145	3.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

FT3



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	26	100.0	0.0	0.0	10.6	2.9	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	10.1	10.6	e*
3	Abbott	11	100.0	0.0	0.0	8.9	4.9	e
4	VIDAS	7	100.0	0.0	0.0	10.0	5.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FT4



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	26	100.0	0.0	0.0	36.7	3.2	e
2	Abbott	11	100.0	0.0	0.0	27.1	6.7	e
3	VIDAS	8	100.0	0.0	0.0	34.6	4.1	e
4	Other methods	8	100.0	0.0	0.0	30.4	7.3	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Testosterone



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	14	100.0	0.0	0.0	14.0	3.7	e
2	Siemens	7	85.7	14.3	0.0	13.6	14.5	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Estradiol



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	12	100.0	0.0	0.0	1178	3.4	e
2	Siemens	5	100.0	0.0	0.0	1643	6.2	e
3	all Participants	5	100.0	0.0	0.0	951	11.3	e*
4	Abbott	5	100.0	0.0	0.0	1096	2.5	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

SHBG



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	16	100.0	0.0	0.0	40.9	4.3	e
2	Abbott	5	100.0	0.0	0.0	45.0	2.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Cortisol



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	21	100.0	0.0	0.0	616	4.4	e
2	Abbott	5	100.0	0.0	0.0	566	6.9	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Progesteron



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	9	100.0	0.0	0.0	39.6	4.4	e
2	Abbott	4	100.0	0.0	0.0	29.5	3.4	e
3	Other methods	6	100.0	0.0	0.0	38.3	9.3	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

DHEAS



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	12	100.0	0.0	0.0	5.08	5.1	e
2	Abbott	4	100.0	0.0	0.0	4.33	9.5	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Luteinizing hormone



QUALAB tolerance : 24 %

Luteinizing hormone (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	14	100.0	0.0	0.0	23.7	6.5	e
2	Siemens	5	100.0	0.0	0.0	20.2	5.8	e
3	Abbott	5	100.0	0.0	0.0	15.7	4.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Follicle-stimulating hormone



QUALAB tolerance : 24 %

Follicle-stimulating hormone (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	13	100.0	0.0	0.0	17.4	4.1	e
2	Abbott	8	100.0	0.0	0.0	17.1	2.5	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Prolactine



QUALAB tolerance : 24 %

Prolactine (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	12.3	5.7	e
2	Cobas/Roche	14	100.0	0.0	0.0	21.0	4.6	e
3	Abbott	6	100.0	0.0	0.0	17.9	9.4	e*

Insulin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	16	100.0	0.0	0.0	496	9.6	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

HGH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	7	100.0	0.0	0.0	11.63	1.7	e
2	Liaison	4	100.0	0.0	0.0	11.25	6.0	e

Freies Testosteron



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	RIA	4	100.0	0.0	0.0	27.0	11.0	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

IGF-1



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	9	88.9	11.1	0.0	105	15.3	e*
2	Other methods	4	100.0	0.0	0.0	73	3.2	e

Troponin T CR



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	822	88.8	7.4	3.8	242.00	13.0	e

D-dimer CR



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	929	82.8	12.8	4.4	0.61	13.9	e
2	Lumira Dx	6	83.3	0.0	16.7	0.57	3.4	e

CKMB- K8



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	6	100.0	0.0	0.0	25.7	18.1	e*

NT-proBNP CR



QUALAB tolerance : 27 %

NT-proBNP CR (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	4	100.0	0.0	0.0	960	7.0	e*
2	Cobas h 232	567	81.4	12.3	6.3	255	17.5	e

PCO2 CCA



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	11	100.0	0.0	0.0	5.63	5.3	e*

PO2 CCA



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	11	90.9	0.0	9.1	12.41	5.8	e

pH CCA



QUALAB tolerance : 1 %

pH CCA ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	10	100.0	0.0	0.0	7.40	0.2	e

Potassium CCA



QUALAB tolerance : 6 %

Potassium CCA (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	5	100.0	0.0	0.0	4.8	1.6	e

Sodium CCA



QUALAB tolerance : 6 %

Sodium CCA (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	4	100.0	0.0	0.0	147.7	1.6	e*

Ferritin



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dimension	6	100.0	0.0	0.0	120.00	9.6	e*
2	Beckman	7	100.0	0.0	0.0	88.20	8.5	e*
3	all Participants	5	60.0	20.0	20.0	120.30	17.3	e*
4	Roche, Cobas	30	96.7	3.3	0.0	110.92	8.8	e
5	Abbott	12	100.0	0.0	0.0	153.20	4.7	e
6	Mini Vidas	7	85.7	14.3	0.0	88.00	10.6	e*
7	AFIAS	26	96.2	3.8	0.0	92.50	9.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Vitamin B12



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	286.00	4.6	e
2	Roche, Cobas	20	100.0	0.0	0.0	307.48	3.7	e
3	Abbott	11	100.0	0.0	0.0	275.76	7.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Folate



QUALAB tolerance : 24 %
(< 10.00: +/- 2.40 nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens	5	100.0	0.0	0.0	7.00	10.3	e*
2	Roche, Cobas	23	100.0	0.0	0.0	7.78	13.2	e
3	Abbott	11	90.9	9.1	0.0	13.45	15.0	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Holotranscobalamine



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	30	100.0	0.0	0.0	98.1	3.5	e
2	Abbott	17	100.0	0.0	0.0	120.2	5.5	e
3	Cobas Biotin suppres	7	100.0	0.0	0.0	67.6	7.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin total Neo



QUALAB tolerance : 18 %

Bilirubin total Neo (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	16	93.7	0.0	6.3	88	2.8	e
2	Dimension	6	100.0	0.0	0.0	106	5.4	e*

Bilirubin direct



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	18	100.0	0.0	0.0	63	6.4	a
2	Dimension	4	100.0	0.0	0.0	52	1.8	e

Bilirubin neonatal



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	10	100.0	0.0	0.0	108	6.6	e
2	Other methods	12	100.0	0.0	0.0	123	3.5	e

PSA



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	17	100.0	0.0	0.0	22.86	3.2	e
2	Abbott	8	100.0	0.0	0.0	21.06	4.7	e
3	AFIAS	11	90.9	9.1	0.0	22.73	8.5	e*

9 additional results were submitted but not published because the method groups were too small. (< results per group)

free PSA



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	11	100.0	0.0	0.0	4.56	4.6	e
2	Abbott	7	100.0	0.0	0.0	5.02	5.3	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

CEA



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	12	100.0	0.0	0.0	25.9	3.9	e
2	Abbott	7	100.0	0.0	0.0	39.5	4.2	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 125



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	8	100.0	0.0	0.0	196.0	4.9	e
2	Abbott	7	100.0	0.0	0.0	300.3	3.4	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 19-9



MQ tolerance : 25 %

CA 19-9 (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	7	100.0	0.0	0.0	126.0	3.8	e
2	Abbott	4	100.0	0.0	0.0	1028.5	4.9	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 15-3



MQ tolerance : 25 %

CA 15-3 (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	10	100.0	0.0	0.0	64.3	5.2	e
2	Siemens	4	100.0	0.0	0.0	71.4	7.0	e*
3	Abbott	7	100.0	0.0	0.0	84.0	7.2	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

AFP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	7	100.0	0.0	0.0	28.2	10.7	d
2	Abbott	5	100.0	0.0	0.0	27.0	3.7	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

HCG qn



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	15	100.0	0.0	0.0	65.7	4.2	e
2	VIDAS	12	91.7	8.3	0.0	28.0	11.3	e*
3	Abbott	7	100.0	0.0	0.0	59.7	5.8	e
4	AFIAS	9	88.9	11.1	0.0	115.0	14.4	e*

9 additional results were submitted but not published because the method groups were too small. (< results per group)

HCG intact



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	5	100.0	0.0	0.0	21.5	3.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

S100



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	6	100.0	0.0	0.0	3.24	3.0	e

NSE



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	5	100.0	0.0	0.0	26.4	6.6	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Thyreoglobulin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	4	100.0	0.0	0.0	159.5	3.5	e
2	Other methods	4	100.0	0.0	0.0	195.4	7.9	e*

CK-MB



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	20	100.0	0.0	0.0	59.5	6.3	e
2	Cobas/Roche	7	100.0	0.0	0.0	17.8	4.2	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

C-Peptid



MQ tolerance : 25 %

C-Peptid (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	7	100.0	0.0	0.0	2.67	4.0	e
2	Other methods	5	100.0	0.0	0.0	2.26	10.6	e*

ACTH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	8	100.0	0.0	0.0	15.70	9.9	e*
2	Liaison	4	100.0	0.0	0.0	31.50	14.5	e*

Procalcitonin



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	6.43	5.2	e
2	Cobas	17	100.0	0.0	0.0	4.95	3.6	e
3	VIDAS	15	100.0	0.0	0.0	4.38	4.4	e
4	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	5.76	16.0	e*
5	Liaison	4	100.0	0.0	0.0	8.91	8.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

EPO



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	124.3	4.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Parathyroid hormone



QUALAB tolerance : 24 %

Parathyroid hormone (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas PTH STAT	11	100.0	0.0	0.0	15.8	6.5	e
2	Cobas	11	100.0	0.0	0.0	12.7	3.2	e
3	IDS	5	80.0	0.0	20.0	23.3	6.8	e*
4	Abbott	7	100.0	0.0	0.0	28.8	12.2	a

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Osmolality



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cryoskopy	22	100.0	0.0	0.0	350	1.3	e

Potassium-K22



QUALAB tolerance : 6 %

Potassium-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	11	100.0	0.0	0.0	3.7	1.5	e

Sodium-K22



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	11	100.0	0.0	0.0	145	1.0	e

Glucose-K22



QUALAB tolerance : 9 %

Glucose-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	11	100.0	0.0	0.0	4.4	1.7	e

Urea-K22



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	11	100.0	0.0	0.0	4.3	6.1	e*

Osmotic Gap



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Formel 1 (2Na+K+Glu+	9	100.0	0.0	0.0	48.0	12.9	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Digoxin



QUALAB tolerance : 24 %

Digoxin (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	4	100.0	0.0	0.0	3.54	5.0	e
2	Other methods	9	100.0	0.0	0.0	3.70	5.7	e

Phenytoin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	84	7.9	e*

Phenobarbital



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	212	5.5	e

Paracetamol



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	4	100.0	0.0	0.0	578.5	5.9	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Vancomycin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	5	100.0	0.0	0.0	20.2	6.7	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Valproat



MQ tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	823.0	4.7	e

Carbamazepin



MQ tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	51.0	6.2	e

Cystatin C



MQ tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	19	94.7	0.0	5.3	1.27	6.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Ethanol



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Others	5	100.0	0.0	0.0	17.4	5.6	e*
2	Abbott	9	100.0	0.0	0.0	17.2	5.2	e
3	Roche, Cobas	21	100.0	0.0	0.0	16.3	4.4	e

Ammonia



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	85.3	2.9	e
2	all Participants	6	100.0	0.0	0.0	107.0	4.3	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Calprotectin



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Bühlmann fCALturbo	21	95.2	0.0	4.8	271	12.6	e
2	Bühlmann Quantum Blu	5	60.0	0.0	40.0	265	19.2	a
3	Liaison	15	100.0	0.0	0.0	120	8.9	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol total Af/b101



QUALAB tolerance : 10 %

Cholesterol total Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	320	99.7	0.0	0.3	5.82	2.2	e
2	Afinion	450	98.2	0.9	0.9	5.72	3.5	e

Cholesterol HDL Af/b101



QUALAB tolerance : 21 %

Cholesterol HDL Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	316	94.6	0.0	5.4	1.24	4.0	e
2	Afinion	449	92.9	0.4	6.7	1.15	5.4	e

Tryglycerides Af/b101



QUALAB tolerance : 18 %

Tryglycerides Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	317	99.4	0.0	0.6	2.16	2.5	e
2	Afinion	451	99.4	0.4	0.2	2.16	4.6	e

Cholesterol PTS



QUALAB tolerance : 10 %

Cholesterol PTS (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	4	50.0	50.0	0.0	5.82	12.1	a

Cholesterol HDL PTS



QUALAB tolerance : 21 %

Cholesterol HDL PTS (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	4	50.0	0.0	50.0	2.33	24.3	e*

Triglycerides



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	4	100.0	0.0	0.0	2.08	7.2	e*

Troponin I AFIAS



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	455	84.0	7.0	9.0	788.13	13.3	e

NT-proBNP AFIAS



QUALAB tolerance : 27 %

NT-proBNP AFIAS (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	345	92.4	3.8	3.8	462.4	11.1	e

Homocystein



MQ tolerance : 30 %

Homocystein (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Beckman	7	100.0	0.0	0.0	10.8	1.8	e
2	all Participants	6	100.0	0.0	0.0	8.3	11.6	e*

Lipase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	31.7	6.5	e
2	Beckman	5	100.0	0.0	0.0	32.0	5.0	e*
3	Roche	27	100.0	0.0	0.0	34.8	5.1	e
4	Fuji Dri-Chem	173	97.1	0.6	2.3	40.9	4.4	e

13 additional results were submitted but not published because the method groups were too small. (< results per group)

Fructosamine



MQ tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	4	100.0	0.0	0.0	292	4.3	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Bicarbonat



MQ tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	6	100.0	0.0	0.0	16.4	3.2	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose CSF



QUALAB tolerance : 9 %
(< 3.30: +/- 0.30 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	15	100.0	0.0	0.0	2.98	1.2	e
2	Other methods	14	100.0	0.0	0.0	2.91	3.0	e

Lactate CSF



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	13	92.3	0.0	7.7	2.53	4.3	e
2	Other methods	10	90.0	0.0	10.0	2.65	5.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Protein CSF



QUALAB tolerance : 15 %

Protein CSF (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	19	100.0	0.0	0.0	0.55	4.2	e
2	Other methods	7	100.0	0.0	0.0	0.55	5.4	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Albumine CSF



MQ tolerance : 20 %

Albumine CSF (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	5	100.0	0.0	0.0	265.00	3.6	e
2	Other methods	4	100.0	0.0	0.0	285.85	1.7	e

CDT



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Immunoassay	5	100.0	0.0	0.0	1.10	4.8	e
2	all Participants	5	80.0	0.0	20.0	0.60	9.5	e*

Tacrolimus



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	10	100.0	0.0	0.0	8.9	9.4	e

Totalprotein E



MQ tolerance : 12 %

Totalprotein E (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	20	100.0	0.0	0.0	71.8	2.9	e

Albumin E



MQ tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	35	97.1	0.0	2.9	62.2	5.2	e

alpha-1-Globuline



MQ tolerance : 30 %

alpha-1-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	12	100.0	0.0	0.0	2.4	6.9	e
2	capillary electropho	23	100.0	0.0	0.0	3.9	9.0	e

alpha-2-Globuline



MQ tolerance : 30 %

alpha-2-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	35	97.1	2.9	0.0	10.0	9.4	e

beta-Globuline



MQ tolerance : 30 %

beta-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	17	100.0	0.0	0.0	8.2	20.7	e*

Beta-1-Globulin



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	13	100.0	0.0	0.0	6.9	7.7	e

Beta-2-Globulin



MQ tolerance : 30 %

Beta-2-Globulin (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	12	100.0	0.0	0.0	3.5	12.4	e

gamma-Globuline



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	15	100.0	0.0	0.0	13.2	17.1	e*

Gamma-Globuline+P



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	21	100.0	0.0	0.0	15.7	6.0	e

Paraprotein



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	5	100.0	0.0	0.0	2.6	88.2	a

Beta-Globuline+P



MQ tolerance : 30 %

Beta-Globuline+P (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	5	100.0	0.0	0.0	10.0	5.0	e

Immunfixation



QUALAB tolerance : 1 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Interpretation	30	96.7	0.0	3.3	5	0.0	e

Folate in Erythrocytes



MQ tolerance : 40 %

Folate in Erythrocytes (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	6	100.0	0.0	0.0	394	18.0	e*
2	Siemens	4	100.0	0.0	0.0	563	12.5	e*
3	Abbott	5	100.0	0.0	0.0	553	7.0	e
4	Roche, Cobas	22	100.0	0.0	0.0	1553	16.9	e

Gallensäure



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	9	100.0	0.0	0.0	68.1	6.8	e
2	all Participants	17	100.0	0.0	0.0	54.5	6.2	e

BNP



QUALAB tolerance : 27 %
(< 75.0: +/- 20.0 ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	7	100.0	0.0	0.0	12.4	42.3	e*

Troponin I Triage



QUALAB tolerance : 24 %

Troponin I Triage (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage high sensitiv	265	88.3	7.9	3.8	731.00	13.0	e
2	Triage Next Gen	10	60.0	10.0	30.0	70.00	16.5	e*

NT-pro BNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	144	91.6	4.2	4.2	287	13.3	e

Vitamin D 25 (OH)



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	LCMS	4	100.0	0.0	0.0	60.8	6.4	e
2	AFIAS	5	100.0	0.0	0.0	60.4	8.8	e*
3	Cobas	18	100.0	0.0	0.0	59.8	7.7	e
4	VIDAS	7	100.0	0.0	0.0	75.0	8.7	e*
5	Other methods	6	66.7	0.0	33.3	63.0	23.3	a
6	Abbott	10	100.0	0.0	0.0	65.7	3.4	e
7	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	66.4	2.4	e

Vitamin D 1,25-(OH)2



MQ tolerance : 27 %

Vitamin D 1,25-(OH)2 (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	4	100.0	0.0	0.0	48.3	3.4	e

AMH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	19	100.0	0.0	0.0	19.8	4.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Inhibin B



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	7	100.0	0.0	0.0	98.9	11.6	e*

Calcitonin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	5	100.0	0.0	0.0	4.7	3.9	e
2	Other methods	7	100.0	0.0	0.0	15.2	4.9	e

IGF-BP3



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	6	100.0	0.0	0.0	3.19	4.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Renin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	8	87.5	12.5	0.0	66.6	16.7	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Aldosteron



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	5	100.0	0.0	0.0	50.4	15.0	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti Thyreoglobulin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	6	83.3	16.7	0.0	16	15.8	e*
2	Roche, Cobas	11	100.0	0.0	0.0	63	5.8	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti TPO



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	12	100.0	0.0	0.0	120	8.4	e
2	Abbott	7	100.0	0.0	0.0	168	9.7	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

TRAK



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	6.64	5.0	e
2	Roche, Cobas	8	100.0	0.0	0.0	4.66	6.8	e
3	Kryptor	4	100.0	0.0	0.0	4.05	10.2	e*

Creatinine WB



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Statsensor i / Nova	81	75.4	16.0	8.6	160	13.1	e

eGFR CDK-EPI WB



MQ tolerance : 30 %

eGFR CDK-EPI WB ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Statsensor i / Nova	4	100.0	0.0	0.0	34	8.5	e*

IL6



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	5	100.0	0.0	0.0	8.6	5.4	e

Pankreas Elastase



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	15	93.3	0.0	6.7	247	19.9	a

Copeptin



MQ tolerance : 30 %

Copeptin (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Kryptor	7	100.0	0.0	0.0	2.5	15.7	a

Occult blood qn



MQ tolerance : 30 %

Occult blood qn (ng/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OC-Sensor	4	100.0	0.0	0.0	1	0.0	e

Amylase-Urine



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	7	100.0	0.0	0.0	61	5.7	e

Pancreatic Amylase-Urine



QUALAB tolerance : 18 %
(< 25.0: +/- 5.0 U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	4	100.0	0.0	0.0	2.1	20.4	e*

Calcium-Urine



MQ tolerance : 9 %
(< 2.00: +/- 0.18 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	17	100.0	0.0	0.0	1.72	3.2	e
2	Abbott	12	100.0	0.0	0.0	1.68	1.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Chloride-Urine



MQ tolerance : 12 %

Chloride-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	12	100.0	0.0	0.0	97	0.9	e
2	Roche, Cobas	14	100.0	0.0	0.0	89	2.2	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose-Urine



QUALAB tolerance : 9 %
(< 3.3: +/- 0.3 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	26	100.0	0.0	0.0	1.5	2.8	e

Magnesium-Urine



MQ tolerance : 12 %

Magnesium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	16	100.0	0.0	0.0	1.66	2.4	e
2	AAS	5	100.0	0.0	0.0	1.74	4.6	e*

Osmolality-Urine



MQ tolerance : 10 %

Osmolality-Urine (mosm/kg)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cryoskopy	21	100.0	0.0	0.0	438	0.9	e

Phosphate-Urine



MQ tolerance : 15 %

Phosphate-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	28	96.4	3.6	0.0	8.1	4.3	e

Potassium-Urine



MQ tolerance : 15 %

Potassium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	38	100.0	0.0	0.0	31	2.0	e

Protein-Urine



QUALAB tolerance : 15 %

Protein-Urine (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	22	100.0	0.0	0.0	181.1	5.5	e
2	Abbott	18	100.0	0.0	0.0	212.9	3.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium-Urine



MQ tolerance : 15 %

Sodium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	38	100.0	0.0	0.0	80	2.4	e

Urea-Urine



MQ tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	36	97.2	2.8	0.0	150	6.4	e

Uric Acid-Urine



MQ tolerance : 15 %

Uric Acid-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	25	100.0	0.0	0.0	0.63	4.3	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Specific Gravity-Urine



MQ tolerance : 5 %

Specific Gravity-Urine ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Refractometer	5	100.0	0.0	0.0	1.013	0.1	e

Ethylglucuronid



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	83.3	0.0	16.7	0.42	11.1	e*

Creatinine U



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	121.1	3.9	e
2	Roche, Cobas	20	100.0	0.0	0.0	112.2	2.4	e
3	Aution	9	77.8	0.0	22.2	80.0	0.0	e
4	AFIAS	17	94.1	0.0	5.9	119.2	7.1	e
5	Afinion	502	95.8	1.6	2.6	113.1	9.1	e
6	Sysmex U	16	81.2	0.0	18.8	150.0	0.0	a
7	Other methods	4	100.0	0.0	0.0	80.0	0.0	e
8	DCA2000/Vantage	159	93.0	1.3	5.7	116.7	6.4	e
9	Siemens Clinitek	26	80.8	0.0	19.2	80.0	0.0	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinin Urin



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	3.2	2.6	e
2	Roche	26	100.0	0.0	0.0	3.5	4.9	e
3	Beckman	4	100.0	0.0	0.0	3.7	9.5	e*
4	Siemens	5	100.0	0.0	0.0	3.2	8.6	e*
5	DCA2000/Vantage	157	93.0	2.5	4.5	3.8	6.9	e
6	Afinion	497	98.6	0.4	1.0	3.2	5.1	e
7	Standard chemistry	4	100.0	0.0	0.0	3.5	8.8	e*
8	Sysmex U	13	69.2	0.0	30.8	4.4	0.0	a
9	Aution	9	77.8	0.0	22.2	4.4	0.0	e
10	Siemens Clinitek	24	83.3	0.0	16.7	4.4	0.2	e
11	Other methods	5	80.0	0.0	20.0	4.4	0.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

HBV NAT qn



HBV NAT qn (Log10 IU/m)

QUALAB tolerance : +/- 0.50 Log10 IU/m

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	7	100.0	0.0	0.0	3.38	4.5	e*

HCV NAT qn



HCV NAT qn (Log10 IU/m)

QUALAB tolerance : +/- 0.50 Log10 IU/m

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	0.00	0.0	e

HIV1 NAT qn



HIV1 NAT qn (Log10 cp/m)

QUALAB tolerance : +/- 0.50 Log10 cp/m

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	4.17	4.4	e*